ZoomMed obtains the american distribution rights of Rx Vigilance “Quick Glance”

Montreal, November 19, 2015 – ZoomMed Inc. (TSX : ZMD) is proud to announce that it has entered into an agreement with Vigilance Santé Inc. for the distribution rights, in the American market, of their widely acclaimed therapeutic advisor, the Rx Vigilance “Quick Glance”. Rx Vigilance “Quick Glance” is one of the cornerstone elements in ZoomMed’s US business plan.

ZoomMed’s President, Yves Marmet, declared: “This agreement will prove to be a turning point in ZoomMed’s quest to become the leading supplier of electronic prescribing solutions to the American medical community. This transaction alone, by adding Rx Vigilance “Quick Glance” to our product portfolio, could increase the anticipated annual sales by several dozen of millions of dollars from the e-prescribing market in the USA. Rx Vigilance “Quick Glance” is a perfect complement to our leading edge ZRx e-prescribing technology. Prescribing doctors often need access to reliable information before making professional decisions. Because their time is in short supply, they want to be able to access information in a timely manner. The Rx Vigilance “Quick Glance” decision support tool addresses that need by providing instant, on-demand access to key professional information.”

Rx Vigilance “Quick Glance” provides prescribing health professionals with an exhaustive pharmaceutical data base with the added intelligence of an electronic therapeutic advisor. The therapeutic advisor is a powerful analysis software. It displays potential problems with each related information specified in the patient’s record. In addition to detecting the interactions, the advisor analyzes the patient’s complete profile according to different criteria and transmits relevant alerts when justified. Within the profile, the therapeutic advisor can identify the following problems: drug interactions, allergies, intolerance and duplication of medications or therapeutic classes.

Since ZoomMed’s decision to clearly establish the US market as its Priority One, it has conducted many meetings over the past twelve months with groups of physicians and various stakeholders in the industry. These meetings have clearly establish the recognition by all physicians of the absolute necessity, in 2015, to have access to a dependable but also functional therapeutic advisor.

According to us the major systems on the market have been developed before the spreading popularity of e-Prescribing applications and consequently have not been developed in the efficient perspective of modern prescribing doctors in live interaction with their patient. Their data base is dependable and exhaustive, but it is not accessible in a concise point-form format that can be functionally interfaced with e-prescribing solutions. Contrarily, for its part, the Rx Vigilance “Quick Glance” has been developed much more recently with the specific purpose of supporting doctors with concise and pertinent information in a live and interactive prescribing environment.

Rx Vigilance “Quick Glance” is already one of the leading therapeutic advisors and the Number 1 drug database in Canada. It has been adopted by 2500+ community pharmacies, 200+ hospitals and medical clinics, 100+ First Nations clinics and 2 Provincial Drug Information Systems in Canada. Beyond all other considerations, the actual penetration rate of the Rx Vigilance “Quick Glance” throughout Canada is a clear indication of its recognition as a solution for the immediate future in the U.S. market.

In conclusion, Yves Marmet added; “ZoomMed’s business plan is clearly stated and we are working diligently to bring it to realization. We are exploring all the avenues, including potential acquisitions in the US, which would rapidly add a substantial physician client base for both our ZRx e-Prescriber and Rx Vigilance “Quick Glance” ”.

 

About ZoomMed

The Company builds and operates “ZoomMed’s communication network”, a clinical information exchange platform between physicians and the various other stakeholders of the healthcare sector, such as pharmacists, specialists, pharmaceutical corporations and private insurers.

The cornerstone of this network is ZoomMed’s “ZRx Prescriber”, a technologically innovative Web application that greatly simplifies the writing of a prescription for the physician. Since it is a stand-alone product, it can easily be integrated to any Electronic Medical Record application (EMR).

For further information on ZoomMed, contact Mr. Yves Marmet, President and Chief Executive Officer (450) 678-5457, Ext 228, info@zoommed.com or visit our Web Site; www.zoommed.com.

-30-

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Statements made in this news release that are not historical facts are “forward-looking statements” and readers are cautioned that any such statements are not guarantees of future performance, and that actual developments or results, may vary materially from those in these “forward-looking” statements.